TLR agonists with anti-tumor efficacy could stimulate DCs, promote Th1-type immune responses, and activate tumor specific T cells [51] However, this CTL’s efficacy might be inhibited by PD-1/PD-L1 and CTLA-4 blockade [52,53]. Here, PDCD1 is linked to neoplasm.